NasdaqGM:NTLABiotechs
Intellia Readies First Phase 3 In Vivo CRISPR Test For HAE Thesis
Intellia Therapeutics (NasdaqGM:NTLA) plans to announce topline results from the first Phase 3 trial of an in vivo CRISPR gene editing candidate for hereditary angioedema.
The upcoming readout will be the first-ever Phase 3 data release for an in vivo CRISPR therapy.
The results are expected to be highly relevant for Intellia's future plans and for gene editing drug development more broadly.
Intellia Therapeutics, trading at around $13.63, sits at the center of attention as it approaches a...